Tuesday, July 2, 2013

Sequenta Secures $20M For Immune Therapeutics

South San Francisco-based biotechnology developer Sequenta has raised $20M in a Series C funding, the firm said today. Sequenta said the round was led by Foresite Capital Management, and also included Mohr Davidow Ventures and Index Ventures. Sequenta said that Jim Tananbaum of Foresite Capital has joined the company's board as part of the funding. The funding will go towards commercial scale up and clinical validation of its lead product, aimed at diagnosis of patients with leukemia or lymphoma. More information »